ASCO® 2023 Insights: “evERA Breast Cancer Phase III Study – Giredestrant + Everolimus vs. Exemestane + Everolimus in Pts With ER+/HER2- Locally Advanced or Metastatic BC”
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research…
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research…
Summary. Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing…
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with…
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple…
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple…
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research…
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors / Albert Grinshpun, cancer, OncoDaily, Oncology, Paolo Tarantino, Ribociclib
